Biopharma investing today requires more than backing strong science—it demands a clear understanding of how policy, pricing, and reimbursement will ultimately determine value. Health economics now shapes investment risk and return well before assets reach the clinic. The ISPOR Healthcare Investment Summit 2026 brings together investors, drug developers, policy leaders, and value strategists to learn how products are evaluated, paid for, and adopted in an evolving policy environment. Sessions will highlight real investment challenges, surface practical insights, and strengthen connections between capital and evidence that can inform smarter, more resilient investment decisions.